KPV
The C-terminal tripeptide of α-MSH studied as a receptor-independent anti-inflammatory in preclinical colitis and IBD models.
Reviewed by Mei Li, PhD, Chief Science Officer
Overview
KPV is a tripeptide made of lysine, proline, and valine (Lys-Pro-Val), corresponding to the last three amino acids of alpha-melanocyte-stimulating hormone (α-MSH 11-13). Published research has examined it as a small, receptor-independent carrier of the anti-inflammatory activity of its much larger parent hormone, but without α-MSH's pigmentation effects. The bulk of the literature is preclinical, concentrated in models of intestinal inflammation. Studies in mice have reported that KPV attenuates chemically induced colitis and lowers pro-inflammatory cytokine expression, and later work extended these observations to a colitis-associated cancer model. A notable feature investigators highlight is that KPV is taken up by the intestinal di/tripeptide transporter PepT1, which is upregulated in inflamed colon tissue, potentially concentrating the peptide where inflammation is greatest. Additional preclinical work has probed effects in skin and airway epithelial cells. To date the evidence base is dominated by animal and in-vitro studies rather than human clinical trials, so conclusions about efficacy or safety in people remain preliminary. KPV is not FDA-approved; it is currently classified as Category 2 and is one of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) July 23-24, 2026 docket for review toward the 503A bulks list.
Mechanism of action
Published mechanistic studies describe KPV acting largely independent of the classical melanocortin receptors. Two features recur in the literature. First, KPV is a substrate for PepT1, a proton-coupled di/tripeptide transporter that is normally expressed in the small intestine and becomes induced in the colon during inflammation; in colitis models, PepT1-mediated uptake was reported to deliver KPV into epithelial and immune cells, and the anti-inflammatory benefit was diminished when PepT1 was absent. Second, once intracellular, KPV has been shown in cell-based work to interfere with the NF-κB signaling cascade, reducing nuclear translocation of NF-κB subunits and dampening downstream transcription of pro-inflammatory genes such as TNF-α, IL-6, and IL-1β; parallel effects on MAP-kinase signaling have also been reported in epithelial cells. Because these actions are described as receptor-independent, researchers have framed KPV as retaining α-MSH's anti-inflammatory signaling while shedding its pigmentary activity.
What published research has examined
The most developed research application is intestinal inflammation. Preclinical studies have examined KPV in dextran sodium sulfate (DSS) and TNBS chemically induced colitis, as well as CD45RB-high T-cell transfer colitis, reporting reduced disease severity and lower inflammatory cytokine levels in treated animals. A 2016 study extended this to colitis-associated colorectal cancer, where KPV reduced tumor number and burden in a PepT1-dependent manner in mice. Because PepT1 concentrates the peptide in inflamed gut tissue, investigators have also explored oral and nanoparticle-based delivery strategies as a way to target the colon in animal models. Beyond the gut, smaller bodies of preclinical work have looked at KPV in skin inflammation and wound-healing contexts and in airway epithelial cells, where receptor-independent NF-κB suppression was observed. Across all of these, the work is preclinical (animal or in-vitro); human clinical trial data establishing efficacy for any condition are not available.
Safety considerations in the literature
Safety characterization for KPV rests almost entirely on preclinical data, and the published record does not include the kind of controlled human trials needed to define a clinical safety profile. In rodent colitis studies KPV was generally reported to be well tolerated at the levels examined, which investigators have noted is consistent with it being a fragment of an endogenous peptide. However, FDA review materials for the July 2026 PCAC docket have noted that peptides in this class are not well characterized, that human evidence of effectiveness and safety is limited, and that immunogenicity has not been formally assessed—points that also apply to KPV. As with any small synthetic peptide, purity, formulation, and route of administration meaningfully affect what is being studied. The literature does not support conclusions about long-term human safety, and KPV remains a research-use compound rather than an approved product.
Key published studies
| Study | Journal | Year | Finding |
|---|---|---|---|
| PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation | Gastroenterology | 2008 | Landmark preclinical study (Dalmasso et al., 134(1):166-178, PubMed 18061177) showing KPV is transported by PepT1 into colonic cells and attenuates chemically induced (DSS and TNBS) colitis in mice while lowering pro-inflammatory cytokines. |
| Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease | Inflammatory Bowel Diseases | 2008 | Kannengiesser et al. (14(3):324-331) reported KPV reduced colonic inflammation across two IBD models (DSS colitis and CD45RB-high transfer colitis); animal-model evidence. |
| Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory Tripeptide KPV in a Murine Model | Cellular and Molecular Gastroenterology and Hepatology | 2016 | Reported that KPV reduced colonic tumor number and burden in a mouse colitis-associated cancer model, with the effect abolished in PepT1-knockout mice, indicating transporter dependence; preclinical. |
Regulatory status
Current status: Category 2 · PCAC July 2026 docket. Category 2 · PCAC July 2026 docket. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.